WO2025006263A2 - Conception de candidats de vaccin universel contre la grippe par réorientation d'antigène - Google Patents

Conception de candidats de vaccin universel contre la grippe par réorientation d'antigène Download PDF

Info

Publication number
WO2025006263A2
WO2025006263A2 PCT/US2024/034466 US2024034466W WO2025006263A2 WO 2025006263 A2 WO2025006263 A2 WO 2025006263A2 US 2024034466 W US2024034466 W US 2024034466W WO 2025006263 A2 WO2025006263 A2 WO 2025006263A2
Authority
WO
WIPO (PCT)
Prior art keywords
antigen
rrc
recombinant
amino acid
alum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2024/034466
Other languages
English (en)
Other versions
WO2025006263A3 (fr
Inventor
Duo XU
Peter S. Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
CZ Biohub SF LLC
Original Assignee
Leland Stanford Junior University
CZ Biohub SF LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University, CZ Biohub SF LLC filed Critical Leland Stanford Junior University
Publication of WO2025006263A2 publication Critical patent/WO2025006263A2/fr
Publication of WO2025006263A3 publication Critical patent/WO2025006263A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Definitions

  • the invention finds application in the fields of human and veterinary medicine.
  • the invention finds application in the fields of human and veterinary medicine.
  • Vaccines are among the most profound accomplishments of biomedical science in combating infectious diseases. The majority of current vaccines protect against infections by eliciting neutralizing antibody responses. Compared to traditional vaccines consisting of entire pathogens (inactivated or attenuated), subunit vaccines, particularly recombinant protein vaccines, are safer and easier to produce but often less immunogenic. Adjuvants are often co-administered with subunit vaccines to enhance the magnitude and durability of host immune responses. The most widely used adjuvant is aluminum hydroxide (alum), which has been safely used in various vaccines since the 1930s. The molecular mechanism of alum/protein interactions is complex.
  • alum aluminum hydroxide
  • Alum is thought to create a ‘depot effect’ that enables the slow release of antigens from the immunization site while activating antigen-presenting cells and inducing cytokine secretion.
  • alum usually induces relatively ‘weak’ immune responses compared to other adjuvants (e.g., lipid-based adjuvants or cytosine phosphoguanosine oligodeoxynucleotides), potentially because antigens desorb from alum in the presence of interstitial fluid or serum and encounter in vivo clearance.
  • Alum has an isoelectric point of 11 and a positive surface charge at physiological pH (7.4), which allows its attraction of negatively charged antigens through electrostatic interactions.
  • Aluminum has a higher affinity for phosphate than hydroxyls, and phosphates can displace hydroxyls on the surface of alum. This ligand exchange reaction affords a stronger force for antigen binding to alum. Antigens with terminal phosphate groups have a high affinity for alum through such ligand exchange reactions.
  • cysteine residues anchored the antigen on alum and shifted antibody responses away from the base of the antigen. See Moyer et al., 2020, “Engineered immunogen binding to alum adjuvant enhances humoral immunity” Nature Medicine 26:430-440; Irvine et al., 2019, “Antigen-adjuvant coupling reagents and methods of use, US Patent No. US 11224648.
  • a recombinant antigen polypeptide comprises a Region of Repetitive Carboxylic Groups (RRC) or a Region of Repetitive Lysyl/Guanidino Groups (RRL) inserted after an amino acid residue in an amino acid sequence with at least 95% amino acid sequence identity to H7 SH HA (SEQ ID NO: 1) over the full-length protein, wherein the amino acid residue corresponds to an amino acid residue selected from the group consisting of amino acid residues 142-152 with reference to SEQ ID NO: 1.
  • RRC Region of Repetitive Carboxylic Groups
  • RRL Region of Repetitive Lysyl/Guanidino Groups
  • the Region of Repetitive Carboxylic Groups (RRC) or a Region of Repetitive Lysyl/Guanidino Groups (RRL) is inserted after an amino acid residue in H7 SH HA (SEQ ID NO: 1), and the amino acid residue is selected from the group consisting of 142W, 143L, 144L, 145S, 146N, 147T, 148D, 149N, 150A, 151A, and 152A.
  • the recombinant antigen polypeptide comprises from N terminus to C terminus continuously: a first antigen fragment having an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 3, an RRC or an RRL, and a second antigen fragment having an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 4.
  • an influenza antigen-adjuvant complex comprising the recombinant antigen polypeptide of any of the claims 1-3 and an adjuvant.
  • the influenza antigen-adjuvant complex is formed by an electrostatic interaction between the RRC or the RRL and an adjuvant.
  • the antigen polypeptide comprises the RRC and wherein the adjuvant is alum (aluminum hydroxide).
  • the antigen polypeptide comprises an RRL, and the influenza antigenadjuvant complex comprises an aluminum-based adjuvant selected from aluminum phosphate and amorphous aluminum hydroxyphosphate sulfate (AAHS).
  • the RRC comprises 8 to 12 amino acids selected from aspartic acid and glutamic acid.
  • the RRC is D8, D9, DIO, Dl l, or D12.
  • N is 11 or X + Y is 11.
  • H7 SH HA is presented as a trimer adsorbed to alum.
  • influenza antigen-adjuvant comprises an alum particle and a plurality of copies of the recombinant antigen polypeptide; the antigen polypeptide comprises an RRC; and the plurality of copies of the antigen polypeptide is associated with the alum particle by electrostatic interaction between the alum particle and the RRC.
  • the recombinant antigen polypeptide comprises one or more auxiliary elements.
  • the one or more auxiliary elements are selected from the group consisting of a polyhistidine tag and a trimerization domain.
  • provided herein is a polynucleotide encoding a polypeptide comprising the recombinant antigen polypeptide described above.
  • a cell comprising the polynucleotide disclosed herein.
  • a vaccine composition comprising a plurality of the influenza antigen-adjuvant complexes of the above.
  • provided herein is a method for eliciting an immune response in a mammal comprising administering the vaccine composition disclosed herein to the mammal.
  • a method of preparing a recombinant vaccine composition comprising (a) expressing a nucleic acid sequence encoding a recombinant antigen polypeptide, wherein the recombinant antigen polypeptide comprises a Region of Repetitive Carboxylic Groups (RRC), or a Region of Repetitive Lysyl/Guanidino Groups (RRL) inserted after an amino acid residue of 144L, 145S, 146N, 147T, 148D, 149N, or 150A of H7 SH HA (SEQ ID NO: 1); and (b) adsorbing the recombinant antigen polypeptide to alum.
  • RRC Region of Repetitive Carboxylic Groups
  • RRL Region of Repetitive Lysyl/Guanidino Groups
  • a method of preparing a recombinant vaccine composition comprising (a) introducing a nucleic acid sequence encoding a recombinant antigen polypeptide to a host cell, wherein the recombinant antigen polypeptide comprises from N terminus to C terminus continuously: a first antigen fragment having an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 3, an RRC or an RRL, and a second antigen fragment having an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 4, thereby producing the recombinant antigen polypeptide; and (b) adsorbing the recombinant antigen polypeptide to alum.
  • the recombinant antigen polypeptide comprises one or more auxiliary elements.
  • the one or more auxiliary elements are selected from the group consisting of a polyhistidine tag and a trimerization domain.
  • a recombinant vaccine composition produced by the method disclosed above.
  • FIG. 1 is a schematic representation of the reorientation of H7 HA by oligoD (poly- Asp) insertion into the head region of H7 HA.
  • H7 HA sequence is based on H7N9 A/Shanghai/2/2013, also referred to as H7 SH - A/Shanghai/2/2013 in this application).
  • FIG. 2A and 2B show the results of the biochemical characterization of H7 HA and reoriented H7 HA (“reoHTHA”).
  • FIG. 2A shows the results of size exclusion chromatography coupled with multi-angle light scattering analysis.
  • FIG. 2B shows the results of protein gel electrophoresis.
  • FIG. 3A and 3B show the thermal melting profiles and the melting temperatures of H7 HA and reoHTHA in solution and in the presence of alum, respectively.
  • FIG. 4A and 4B show the epitope accessibility of reoHTHA on alum by ELISA.
  • FIG. 4 A shows the binding of head-directed mAbs (“FluA-20”) and stem-directed mAbs (“MEDI8852” and “FI6v3”) to the reoHTHA on streptavidin-coated plates.
  • FIG. 4B shows the binding of monoclonal antibodies to the reoHTHA on alum-coated plates.
  • vaccine or “vaccine polypeptide” refers to the antigen (polypeptide) portion of a vaccine preparation
  • “vaccine composition” refers to the antigen (polypeptide) in combination with an adjuvant (alum) and optionally other excipients.
  • a “recombinant subunit vaccine” or “recombinant subunit vaccine polypeptide” refers to a recombinantly produced polypeptide intended for administration to a subject to elicit a protective immune response.
  • Other terms used interchangeably with recombinant subunit vaccine include “recombinant polypeptide vaccine” “biosynthetic polypeptide vaccine,” and “genetically engineered polypeptide vaccine.”
  • an “antigen polypeptide” or “antigenic portion” is a polypeptide or portion of a polypeptide that encodes a pathogen protein or portion of a pathogen protein (“pathogen antigen polypeptide”), or encodes a disease antigen or portion of disease antigen (“disease antigen polypeptide”), and elicits a desired protective immune response against the pathogen or disease antigen.
  • a “disease antigen” refers to an antigen that is a target of a therapeutic vaccine, such as a cancer antigen. See Tagliamonte et al., 2014, “Antigen-specific vaccines for cancer treatment” Hum Vaccin Immunother. 10(11):3332-3346. doi : 10.4161/21645515.
  • a “subject” to which a vaccine is administered may be a human or may be a non-human animal (e.g., a pet, such as a cat or dog, livestock, such as cows, sheep, pigs, goats, fish, and poultry).
  • RRC Repetitive Carboxylic Groups
  • RRC-encoding sequence is a nucleic acid sequence that encodes an RRC.
  • an “aspartate residue” is an amino acid residue in a polypeptide, having the side chain CH2COOH. Aspartate is an a-amino-acid residue anion resulting from the deprotonation of the carboxy group of an aspartic acid residue and is generally the form found in physiological conditions.
  • the terms “aspartic acid,” ’’aspartate,” “aspartic acid residue,” and ’’aspartate residue,” are often used interchangeably in the literature and are equivalent terms as used herein. Aspartate is represented as “D” or “Asp.”
  • a “poly- Asp sequence” refers to 6 or more contiguous aspartate residues in an RRC portion of a recombinant polypeptide vaccine made as disclosed herein.
  • a “poly-Asp encoding sequence” is a nucleic acid sequence that encodes multiple contiguous aspartate residues. In most systems aspartate is encoded by the codons GAT and GAC.
  • a “glutamate residue” is an amino acid residue in a polypeptide, having the side chain CH2CH2COOH.
  • Glutamate is an a-amino-acid residue anion resulting from the deprotonation of the carboxy group of a glutamic acid residue and is generally the form found in physiological conditions.
  • the terms “glutamic acid,” “glutamate,” “glutamic acid residue,” and “glutamate residue,” are often used interchangeably in the literature and are equivalent terms as used herein. Glutamate is represented as “E” or “Glu.”
  • a “poly-Glu sequence” refers to 6 or more contiguous glutamate residues in an RRC portion of a recombinant polypeptide.
  • a “poly-Glu encoding sequence” is a nucleic acid sequence that encodes multiple contiguous aspartate residues. In most systems aspartate is encoded by the codons CAG and CAA.
  • RRC-containing polypeptide is an antigenic polypeptide that can be used as a component of a vaccine and contains an RRC.
  • introduction in the context of an RRC, “introduction,” “installation,” and “insertion” are used interchangeably to refer to addition to and/or modification of a nucleic acid sequence encoding an RRC, e.g., poly- Asp or poly-Glu, for expression of an RRC- containing polypeptide (antigen).
  • a polypeptide expressed from such a nucleic acid i.e., a polypeptide having an RRC inserted
  • RRC-encoding codons are carried out using any suitable method, including molecular cloning and de novo synthesis of a polynucleotide.
  • an insertion can be characterized as a “terminal insertion” or an “intervening insertion.”
  • a “terminal” poly-Asp/poly-Glu/RRC sequence refers to a sequence found at the amino- or carboxy-terminus of a recombinant protein vaccine polypeptide.
  • a poly-Asp/poly-Glu/RRC sequence that is at the amino-terminal but for an immediately preceding a single methionine can be considered a terminal RRC.
  • the amino- or carb oxy -terminus of a recombinant protein refers to a terminus of a mature or processed protein or protein fragment as combined with alum and incorporated into the vaccine composition.
  • the terminal RRC can be positioned at the terminus of the mature protein.
  • the terminal RRC encoding sequence can be positioned between codon corresponding to the C- terminus of the signal peptide and the codon corresponding to the N-terminus of mature polypeptide.
  • the terminal RRC may be positioned such that it is located at the N- or C- terminus of the processed mature protein.
  • the terminal RRC may be positioned such that it is located at the N- or C- terminus of the processed (e.g., cleaved) protein.
  • a terminal RRC may be positioned at the terminus of the polypeptide product that is combined with alum.
  • the form immobilized on alum refers to the antigen polypeptide associated with alum in a vaccine composition.
  • the form immobilized on alum may refer to a mature polypeptide after removal of a signal peptide and cleavage.
  • the antigen polypeptide presented on alum is member of a multimer (e.g., trimer).
  • the multimer may be a homomultimer or a heteromultimer.
  • an RRC “at” the amino- or carboxy-terminus of a polypeptide means that in the form immobilized on alum the RRC is a terminal sequence.
  • an RRC “near” the amino- or carboxy-terminus of a polypeptide means that in the form immobilized on alum the RRC within twenty-five (25) residues of a polypeptide terminus, i.e., the twenty-fifth residue from the polypeptide terminus is part of the RRC.
  • the RRC near a terminus is within 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, or 2 residues of a polypeptide terminus.
  • an “intervening” RRC sequence refers to an RRC that is not at the amino- or carboxy-terminus of an antigen polypeptide in the form immobilized on alum.
  • An intervening RRC can be an insertion at a position within an antigen polypeptide (a “contiguous intervening” sequence) or may be a substitution that replaces residues of the unmodified antigen. In either case, additional amino acid flanking one or both ends of the RRC sequence may be included in the introduced sequence.
  • a “contiguous intervening” poly-Asp/poly-Glu/RRC sequence refers to a poly-Asp/poly-Glu/RRC sequence within a polypeptide, where the poly-Asp/poly- Glu/RRC separates and is contiguous with two sequences that are contiguous in the unmodified antigen (e.g., a pathogen protein found in nature).
  • sequence identity in reference to similarity of two proteins (a target protein and a reference protein) or two nucleic acids (a target nucleic acid and a reference nucleic acid) is a quantification of identity of amino acids or nucleobases when the reference and target sequence are optimally aligned.
  • Software tools that can be used for performing sequence alignment are well known in the art, including those for performing pairwise sequence alignment (for example, SSEARCH) or multiple sequence alignment (for example, ClustalW). Sequence identity can be determined manually by inspection, especially when the target and reference have greater than 90% identity.
  • percent identity to a reference nucleic acid sequence can be determined using a BLAST or BLAST 2.0 comparison program (described in Altschul et al. (1990) J. Mol. Biol. 215: 403-410 and Altschul et al. (1977) Nucleic Acids Res. 25: 3389-3402, respectively) with default parameters.
  • BLASTP with default parameters can be used to determine percent to a reference polypeptide sequence.
  • the BLASTP program uses as defaults a word size (W) of 3, an expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff & Henikoff, Proc. Natl. Acad. Sci. USA 89: 10915 (1989)).
  • Software for BLAST analyses is publicly available through the National Center for Biotechnology Information (NCBI) website.
  • promoters or other regulatory elements such as enhancers, is "operably linked" to a nucleic acid sequence when they affect to the expression of RNA from the nucleic acid sequence.
  • an RRC-containing antigenic polypeptide can be described as a “derivative” of a non-RRC polypeptide (e.g., a naturally occurring pathogen protein, candidate subunit in development) when the RRC-containing antigenic polypeptide (“parental polypeptide”) shares sequence identity with at least a portion of the non-RRC antigenic polypeptide and elicits an immune response specific for the non-RRC polypeptide.
  • parental polypeptide e.g., a naturally occurring pathogen protein, candidate subunit in development
  • parental polypeptide shares sequence identity with at least a portion of the non-RRC antigenic polypeptide and elicits an immune response specific for the non-RRC polypeptide.
  • a derivative of a polypeptide may have at least about 50% sequence identity, at least about 60% sequence identity, at least about 70% sequence identity, at least about 80% sequence identity, or at least about 90% sequence identity with a corresponding “parental” polypeptide.
  • the term “substantially similar,” when referring to sequence similarity, refers to that an amino acid sequence shares at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the reference amino acid sequence.
  • This disclosure describes new vaccine compositions comprising a modified antigen bound to the surface of an adjuvant or carrier by electrostatic interactions.
  • the presentation of an antigen in a defined orientation on an adjuvant surface can be used to alter epitope accessibility and redirect an immune response toward specific epitopes.
  • a targeted immune response can be directed toward less dominant but more desirable epitopes of the antigen than is possible using conventional adsorption methods.
  • a targeted immune response can be directed to an epitope(s) that is conserved among members of a family of related antigens.
  • influenza hemagglutinin (HA) proteins in which dominant immunogenic epitopes are not conserved among family members, and less dominant epitopes are conserved.
  • HA hemagglutinin
  • a vaccine described herein can elicit antibodies that are cross-reactive and protective against diverse influenza strains.
  • the H7 HA protein is genetically engineered to introduce an amino acid sequence rich in charged residues (e.g., poly(aspartic acid), poly(glutamic acid), poly(lysine), and poly(arginine) at a defined location in the target protein.
  • the defined location is the amino acid residue corresponding to an amino acid residue selected from the group consisting of amino acid residues 142-152 with reference to SEQ ID NO: 1.
  • the amino acid residue is selected from the group consisting of 142W, 143L, 144L, 145S, 146N, 147T, 148D, 149N, 150A, 151 A, and 152A with reference to SEQ ID NO: 1.
  • Vaccine polypeptides modified by introduction of a Region of Repetitive Carboxylic Groups (RRC).
  • RRC Region of Repetitive Carboxylic Groups
  • the modification introduces a region rich in aspartate (D) and/or glutamate (E) causing the polypeptide to associate with a negatively charged region of an alum aggregate (comprising aluminum hydroxide).
  • Vaccine polypeptides modified by introduction of a Region of Repetitive Lysyl/Guanidino Groups (RRL).
  • the modification introduces a region rich in lysine (K) and/or arginine (R), causing the polypeptide to associate with a negatively charged region of an aluminum-based adjuvant, such as aluminum phosphate and amorphous aluminum hydroxyphosphate sulfate (AAHS).
  • an aluminum-based adjuvant such as aluminum phosphate and amorphous aluminum hydroxyphosphate sulfate (AAHS).
  • Vaccine polypeptides modified by introduction of an RRC or RRL and adsorbed to lipid nanoparticles (LNPs) used as carriers or adjuvants (e.g., liposomal saponin, monophosphoryl lipid A).
  • LNPs lipid nanoparticles
  • Adjuvants for Vaccines e.g., liposomal saponin, monophosphoryl lipid A.
  • LNPs Liposome Formulation (ALF) family of vaccine adjuvants
  • ALF Army Liposome Formulation family of vaccine adjuvants
  • the surface charge of LNPs can be fine-tuned by the lipid composition using art-known means.
  • RRC -modified antigens will adsorb onto positively-charged LNPs and RRL-modified antigens will adsorb onto negatively-charged LNPs.
  • This disclosure describes exemplary recombinant protein vaccines developed against influenza viruses expressing H7 HA.
  • these proteins may be modified by addition of an RRC or RRL and delivered using, for example but not limited to, an alum adjuvant.
  • Influenza A viruses are the influenza viruses known to cause flu pandemics. Influenza A viruses are divided into subtypes based on two proteins on the surface of the virus: hemagglutinin (HA) and neuraminidase (NA). There are 18 known HA subtypes and 11 known NA subtypes. For example, H7N9 has an H7 HA protein and an N9 NA protein. Exemplary H7 HA proteins are shown in Table 1. Table 1 Exemplary influenza H7 HA proteins:
  • Influenza Hemagglutinin is a glycoprotein found on the surface of influenza viruses. It is responsible for binding the virus to cell membranes, such as, cells in the upper respiratory tract or erythrocytes. HA is also responsible for the fusion of the viral envelope with the endosomal membrane, after the pH drops in the endosome. HA is a homotrimeric integral membrane glycoprotein. HA is expressed as a precursor protein (referred to as HAO) that trimerizes and then is cleaved into two smaller polypeptides — the HA1 and HA2 subunits, which remain complexed. The mature form of HA is thus a trimer of HA1-HA2 heterodimers.
  • HAO precursor protein
  • the HA1 subunit includes a globular head region containing the hemagglutinin receptor binding site that interacts with sialic acid on the surface of eukaryotic cells.
  • the HA2 subunit includes a long, helical chain, a transmembrane region, and a cytoplasmic region. A portion of the HA1 subunit and the helical chain portion of the HA2 subunit are referred to as the stem region of the Hemagglutinin (HA) protein.
  • the head region of HA appears to be immunodominant, meaning that during viral infection or during vaccination, subjects often produce antibodies predominantly against the head region.
  • the head region has significantly higher sequence variability when compared to the stem region, and antibodies against it are often not protective against challenges with other viral isolates.
  • the HA stem domain is highly conserved and appears to contain broadly neutralizing epitopes. As such, antibodies directed against the HA stem domain may protect against many strains of the virus.
  • regions of a polypeptide with a high density of carboxylic groups known as a Region of Repetitive Carboxylic Croups or “RRC”, further discussed below, are introduced into a H7 influenza virus antigen polypeptide to produce an “enhanced antigen.”
  • RRC Region of Repetitive Carboxylic Croups
  • enhanced antigens increase humoral antibody responses and increase the neutralization potency of the antibody response relative to administration of an unmodified antigen-alum complex.
  • the antigenic-alum complexes of the invention may be designed to present antigens in a predetermined orientation.
  • the orientation directs the immune system to generate antibodies against a specific region, or epitope, of the antigen, a process referred to herein as “immunofocusing.”
  • the orientation can be used to elicit production of neutralizing antibodies.
  • H7 HA for example, H7 NT, H7 SH with the desired “upside down” configuration by inserting poly-Asp at various locations, such as T165 (with reference to UniProt Accession No. Q82794), G205 (with reference to UniProt Accession No. Q82794), S136 (with reference to UniProt Accession No. R4NN21), DI 66 (with reference to UniProt Accession No. R4NN21), G205 (with reference to UniProt Accession No. R4NN21), respectively.
  • poly-Asp at various locations, such as T165 (with reference to UniProt Accession No. Q82794), G205 (with reference to UniProt Accession No. Q82794), S136 (with reference to UniProt Accession No. R4NN21), DI 66 (with reference to UniProt Accession No. R4NN21), G205 (with reference to UniProt Accession No. R4NN21), respectively.
  • poly-Asp at various locations
  • Engineered H7 HA constructs comprising these poly-Asp insertions were not able to produce detectable amount of proteins; thus, they cannot be used to produce vaccines.
  • Table 2 lists a number of such engineered H7 HA constructs; no protein expression of these constructs was detected by Western blots.
  • Table 2 Certain poly-Asp insertion into the H7 HA proteins resulted in loss of expression in a cell culture system.
  • a recombinant antigen polypeptide comprises a Region of Repetitive Carboxylic Groups (RRC) or a Region of Repetitive Lysyl/Guanidino Groups (RRL) inserted into H7 SH HA (SEQ ID NO: 1) or an amino acid sequence with at least 90%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% amino acid sequence identity to H7 SH HA (SEQ ID NO: 1) over the full-length protein.
  • RRC Region of Repetitive Carboxylic Groups
  • RRL Region of Repetitive Lysyl/Guanidino Groups
  • RRC and insertion location of the RRC may vary and they are further disclosed below in sections below entitled “RRC TYPES AND PROPERTIES” and “SITE OF RRC INSERTIONS.”
  • the RRC or RRL is inserted into an amino acid residue that is selected from the group consisting of amino acid residues 142-152 with reference to SEQ ID NO: 1.
  • the RRC or RRL is inserted after an amino acid residue in H7 SH HA (SEQ ID NO: 1), and the amino acid residue is selected from the group consisting of 142W, 143L, 144L, 145S, 146N, 147T, 148D, 149N, 150A, 151A, and 152A.
  • the recombinant antigen polypeptide comprises from N terminus to C terminus continuously: a first antigen fragment having an amino acid sequence with at least 90%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% amino acid sequence identity to SEQ ID NO: 3, an RRC or an RRL, and a second antigen fragment having an amino acid sequence having at least 90%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% amino acid sequence identity to SEQ ID NO: 4.
  • the term “continuously” refers to that there is no intervening amino acid residue between any two of the 1) the first antigen fragment, 2) the RRC or RRL, and 3) the second antigen fragment.
  • RRCs are rich in glutamic acid and/or aspartic acid, both of which are acidic amino acids with a side chain containing a terminal carboxyl group.
  • RRCs are sometimes categorized as TYPE 1, TYPE 2, TYPE 3, or TYPE 4 RRCs. Each type of RRC begins with a glutamic acid or aspartic acid residue and ends with a glutamic acid or aspartatic acid residue. In some embodiments the RRC contains aspartic acid residues and does not contain glutamic acid residues. In some embodiments the RRC contains glutamic acid residues and does not contain aspartic acid residues.
  • an RRC in a polypeptide, can be described as the region of contiguous amino acid residues having a D or E at the amino end of the RRC, a D or E at the carboxy end of the RRC and having the properties of a TYPE 1-4 RRC. It will be recognized that in some cases an RRC may be inserted adjacent a D or E containing sequence present in the unmodified antigen. For example, in SEQ ID NO: 6, a sequence DDDDDDDDDDD is inserted into the wild type sequence “. LLSNTDNAA..” resulting in “LLSNTDDDDDDDDDDDDNAA” In the resulting modified protein the RRC has the sequence DDDDDDDDDD including the added [D]n sequence and the D from the wildtype H7 SH protein.
  • a TYPE 1 RRC contains a poly-Asp sequence (“poly- Asp” or “[Asp]x” or “poly- D” or “oligoD”).
  • poly-Asp sequence (“poly- Asp” or “[Asp]x” or “poly- D” or “oligoD”).
  • Several RRCs described in Examples are TYPE 1 RRCs. In some embodiments N is 6-40 or 8-20 or 8-18.
  • a TYPE 2 RRC contains a poly-Glu sequence (“poly-Glu” or “[G1U]N” or “poly- E”). In some embodiments N is 6-40 or 8-20 or 8-18.
  • the term “TYPE 3 RRC” includes such copolymers, as well as TYPE 1 and TYPE 2 RRCs.
  • Residues in a TYPE 3 RRC can be described, without limitation, as a copolymer, a block copolymer, an alternating copolymer, or a random copolymer, such as DEDEDEDEDE (alternating copolymer), DDDEEEDDDEEE (block copolymer) or, e.g., EEEDEDDDEDEEED (random copolymer).
  • a TYPE 4 RRC has a high density of Asp and/or Glu, but may include other residues as well. Examples of TYPE 4 RRCs are the sequences DDDDDLEEEEE and DEDEDDLEGEED. “High density” means that at least 50% of residues in the RRC are Asp or Glu.
  • “High density” means that at least 50%, at least 60%, at least 75% or at least 80% of residues in the RRC are Asp or Glu. It will be apparent that the first residue of a TYPE 4 RRC will be D or E and the last residue of a TYPE 4 RRC will be D or E. It will also be apparent that all TYPE 1-3 RRCs (each having 100% Asp or Glu) are also TYPE 4 RRCs. Table 3 and Table 4 list various types of RRCs.
  • RRCs which at least 80% of residues in the RRC are Asp or Glu
  • RRCs which at least 50% of residues in the RRC are Asp or Glu
  • the non-D non-E residues in a TYPE 4 RRC are small, non-polar and neutral amino acids such as glycine, leucine or alanine.
  • the RRC does not contain lysine or arginine (positively charged residues).
  • the antigen protein is modified by introduction of two or more RRCs.
  • the RRCs are positioned in different flexible loops, but are close in three- dimensional space.
  • the number of amino acid residues in an RRC is generally in the range of 6 to 40. Often the RRC has a length of 8 to 20 residues. Generally, an RRC contains at least six residues that are D or E, preferably at least eight residues that are D or E. In some embodiments, the length of the RRC insertion sequence) is 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15. However, in some embodiments the RRC sequence comprises a greater or smaller number of Asp residues, such as 2 to 30 or 3 to 20 Asp residues.
  • the RRC is 8 residues (e.g., 8D). In some cases, the RRC is 11 residues (e.g., 11D). As shown below in Example 2 and FIG. 3B, FIG. 4A and 4B, 11D insertion into H7 HA (SEQ ID NO: 1) resulted in complete binding of the engineered H7 HA to alum and the desired “upside down” configuration.
  • alum refers to insoluble aluminum hydroxide (also called aluminum oxyhydroxide) suitable for use as an adjuvant in humans and nonhuman animals. See HogenEsch et al., 2018, “Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want.” npj Vaccines 3, 51. doi.org/10. 1038/s41541-018-0089-x; also see Baylor et al, 2002, “Aluminum salts in vaccines— US perspective” Vaccine 20 Suppl 3:S18-23. doi: 10.1016/s0264-410x(02)00166-4.
  • Alum has been described as aggregates of aluminum hydroxide nanoparticles or microparticles. See Harris et al. 2012, Alhydrogel(R) adjuvant, ultrasonic dispersion and protein binding: a TEM and analytical study. Micron 43, 192-200; Li et al., 2017 “Aluminum (Oxy)Hydroxide Nanosticks Synthesized in Bicontinuous Reverse Microemulsion Have Potent Vaccine Adjuvant Activity” ACS Appl Mater Interfaces. 2017;9(27):22893-22901.
  • alum particles is used to describe to alum of various sizes and shapes, provided the alum is suitable for use as an adjuvant.
  • Alum is available from a variety of commercial sources.
  • ALHYDROGEL® type adjuvant is commercially available (CRODA, Invivogen).
  • an aluminum-based material with a surface negative charge is uses as an aluminum-based adjuvant.
  • examples include aluminum phosphate and amorphous aluminum hydroxyphosphate sulfate (AAHS).
  • AAHS amorphous aluminum hydroxyphosphate sulfate
  • Vaccine anigen polypeptides modified by introduction of a Regions of Repetitive Lysyl/Guanidino Groups (“RRL”) may be combined with aluminum-based adjuvants to prepare vaccines of the invention.
  • RRC recombinant subunit vaccines can be carried out as desired.
  • recombinant DNA methodology may be used to modify an antigen-encoding sequence by site-specific introduction of an RRC encoding sequence. See, e.g., Irwin et al., 2012, “In-Fusion® Cloning with Vaccinia Virus DNA Polymerase” In: Isaacs S. (eds) Vaccinia Virus and Poxvirology. Methods in Molecular Biology (Methods and Protocols), vol 890. Humana Press, Totowa, NJ. doi.org/10.1007/978- 1-61779-876-4 2.
  • introduction of an RRC does not imply use of any particular methodology. Exemplary methods include insertion and ligation, homologous recombination, and introduction using a CRISPR/CAS system.
  • Recombinant subunit polypeptide vaccines can be produced using any suitable method, including expression as heterologous proteins in recombinant systems.
  • Exemplary expression systems are well known and include bacteria, yeast, insect cell, mammalian cell, plant and transgenic animal platforms. See, e.g., Cid and Bolivar, 2021, “Platforms for Production of Protein-Based Vaccines: From Classical to Next-Generation Strategies” Biomolecules 77, 1072.doi.org/10.3390/ bioml 1081072; also see Man Wang et al., 2016, “Recent advances in the production of recombinant subunit vaccines in Pichia pasloris. Bioengineered , 155-165, DOE 10.1080/ 21655979.2016.1191707.
  • a recombinant subunit vaccine can be prepared by (a) obtaining a first polynucleotide comprising a sequence that encodes an antigen polypeptide; (b) introducing a RRC-encoding nucleic acid sequence into the sequence that encodes the antigen polypeptide, thereby producing a second polynucleotide encoding a chimeric protein sequence having (i) a RRC portion and (ii) an antigen polypeptide sequence portion(s).
  • the nucleic acid sequence encoding the chimeric protein sequence linked to a promoter that drives transcription of the protein-encoding a sequence is typically, the nucleic acid sequence encoding the chimeric protein sequence linked to a promoter that drives transcription of the protein-encoding a sequence.
  • the chimeric protein encoded by the second polynucleotide is expressed to produce a RRC containing vaccine antigen polypeptide.
  • the polypeptide can be expressed using art-known methods, e.g., as discussed above, such as a cell based or cell-free expression system.
  • the vaccine polypeptide can be purified using routine methods.
  • the invention provides vaccine polypeptides and vaccine compositions prepared using the methods described herein.
  • the method further includes the step of adsorbing the polypeptide to alum to produce a protein-alum complex. See Section XII below, titled “ Adsorbing Antigen to Alum.”
  • the method further includes the step of combining the protein-alum complex with excipients. Components (e.g., protein, alum, excipient) can be combined in any order.
  • the recombinant subunit vaccine comprises a sequence that elicits an immune response, such as an immune response against a pathogen.
  • the antigen polypeptide has a sequence found in nature (e.g., a polypeptide expressed by the pathogen). Insertion of the RRC sequence results in a protein in which a pathogen sequence is close to or adjacent to a RRC in an arrangement not found in nature. In a related approach insertion of the RRC sequence results in a protein in which the RRC is adjacent to a pathogen sequence.
  • a recombinant subunit vaccine containing a RRC or other RRC sequence can be recognized by reference to naturally occurring sequences identified in database such as Genbank or Uniprot.
  • a hallmark of some vaccine polypeptides is an RRC adjacent to or near a known pathogen sequence. It will be understood that a characteristic of the recombinant subunit vaccine polypeptides is the presence of RRC near or adjacent to known or naturally occurring sequences (e.g., pathogen sequences), i.e., an arrangement not found in nature as can be readily deduced by reference to a sequence database.
  • known or naturally occurring sequences e.g., pathogen sequences
  • the antigen polypeptide is a component of a vaccine that is approved or licensed by a regulatory agency, as is discussed in greater detail herein below.
  • the RRC is inserted to improve the properties of the known vaccine.
  • the antigen polypeptide is a known (e.g., published) vaccine polypeptide candidate.
  • the RRC is inserted to improve the properties of the candidate vaccine.
  • the hallmarks a RRC-containing recombinant subunit vaccine can be recognized by reference to a sequence database, having the hallmark of RRC adjacent to or close a known sequence of a licensed vaccine polypeptide or vaccine polypeptide candidate.
  • a recombinant antigen polypeptide disclosed herein comprises a Region of Repetitive Carboxylic Groups (RRC) or a Region of Repetitive Lysyl/Guanidino Groups (RRL) inserted after an amino acid residue in an amino acid sequence with at least 95% amino acid sequence identity to H7 HA (SEQ ID NO: 1) over the full-length protein.
  • the recombinant antigen polypeptide comprises SEQ ID NO: 1.
  • the RRC or RRL is inserted into the amino acid sequence after an amino acid residue corresponding to amino acid residues 142-152 with reference to SEQ ID NO: 1.
  • a recombinant antigen polypeptide disclosed herein comprises from N terminus to C terminus continuously: a first antigen fragment having an amino acid sequence with at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 3, an RRC or an RRL, and a second antigen fragment having an amino acid sequence having at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 4.
  • Optimal sites of insertion were determined.
  • the effects of RCC insertion were assessed by comparing thermal melting relative to a reference sequence. Retention of conformational epitopes were assessed by determining the effect of the insertion using panels of antibodies. Methods of determining the optimal sites of insertion are also disclosed in WO2023064631.
  • the effect of alum binding by the RRC-containing antigen relative to the wild-type antigen were assessed in a variety of ways, including as described in Examples 1-2, FIG. 2A and 2B.
  • the ability of adjuvated antigen to elicit an immune response can be determined using art-known methods such as measuring antibody response including specific IgG production including. See Example 4 and FIG. 5, 11, 14, and 18 of WO2023064631. In one approach, the ability of vaccination to generate neutralizing antibodies is assessed. See Example 1. Methods of assessing ability of vaccination to generate neutralizing antibody is also described in WO2023064631, Example 4.
  • the position of an inserted RRC can be used to control the orientation of the antigen polypeptide relative to the alum surface, providing methods for immunofocusing.
  • the control of antigen orientation on alum by introducing RRC to different locations on antigen proteins has several advantages.
  • the RRC-containing antigenic proteins of this disclosure are useful as vaccine immunogens that can direct the immune system of a subject immunized with such vaccine immunogens to generate antibodies against a specific region, or epitope, of a protein that is known to be productive or neutralizing in the case of an infection
  • PMD Protected, Modify, Deprotect
  • the invention provides a vaccine composition
  • a vaccine composition comprising antigen protein molecules adsorbed to alum particles, wherein the antigen protein molecules comprises a Region of Repetitive Carboxylic Groups and wherein a majority of the of the antigen protein molecules in the composition that are adsorbed to alum have the same orientation relative to a surface of the alum particle to which it is adsorbed. Orientation can be determined as described above (in section captioned “Site of RRC Insertion”) and as described in Examples 2. In one approach, antigen proteins in antigen protein-alum complexes have the same orientation relative to the alum surface when a panel of 4, 5, or more monoclonal antibodies against the protein exhibit substantially similar binding patterns.
  • auxiliary element refers to a functional element in an RRC- containing polypeptide sequence that are not present in the antigen sequence that is modified by insertion of the RRC into, e.g., naturally occurring sequence.
  • auxiliary elements include tags for analysis or purification (e.g., a histidine tag or AviTag, and the like), spacer elements (e.g., a glycine-serine spacer having the structure [N]3-5 where N is glycine or serine, e.g., GGS), and trimerization domains (e.g., foldon, GCN4, GCN4- plql).
  • tags for analysis or purification e.g., a histidine tag or AviTag, and the like
  • spacer elements e.g., a glycine-serine spacer having the structure [N]3-5 where N is glycine or serine, e.g., GGS
  • trimerization domains e.g., foldon, GCN4, G
  • Gly-Ser spacers provide flexibility in the polypeptide that allows the RRC (or an auxiliary element) to adopt orientations to facility binding to alum.
  • Trimerization domains may be included in the vaccine preparation. Influenza Hemagglutinin (HA) proteins are found in nature as trimers.
  • a trimerization domain is included in the RRC-containing polypeptide stabilize the trimeric structure of the antigen complex.
  • the trimerization domain foldon (or GCN4) in these polypeptides can be replaced with GCN4 (or foldon) or any other trimerization domain.
  • some antigen polypeptides will comprise a dimerization domain or other multimerization domain.
  • Embodiment 7 The influenza antigen-adjuvant complex of any one of the preceding embodiments, wherein the antigen polypeptide comprises an RRL, wherein the influenza antigen-adjuvant complex comprises an aluminum-based adjuvant selected from aluminum phosphate and amorphous aluminum hydroxyphosphate sulfate (AAHS).
  • Embodiment 9 The influenza antigen-adjuvant complex of any one of the preceding embodiments, wherein the RRC comprises 8 to 12 amino acids, wherein each of the 8 to 12 amino acids is selected from the group consisting of aspartic acid and glutamic acid.
  • Embodiment 12 The influenza antigen-adjuvant complex of any one of the preceding embodiments, wherein N is 11 or X + Y is 11.
  • Embodiment 13 The influenza antigen-adjuvant complex of any one of the preceding embodiments, wherein H7 SH HA is presented as a trimer adsorbed to alum.
  • Embodiment 14 The influenza antigen-adjuvant complex of any one of the preceding embodiments that comprises an alum particle and a plurality of copies of the recombinant antigen polypeptide, wherein the antigen polypeptide comprises an RRC, wherein the plurality of copies of the antigen polypeptide is associated with the alum particle by electrostatic interaction between the alum particle and the RRC.
  • Embodiment 15 The influenza antigen-adjuvant complex of any one of the preceding embodiments in which the recombinant antigen polypeptide comprises one or more auxiliary elements.
  • Embodiment 16 The influenza antigen-adjuvant complex of any one of the preceding embodiments, wherein the one or more auxiliary elements are selected from the group consisting of a polyhistidine tag and a trimerization domain.
  • Embodiment 17 A polynucleotide encoding a polypeptide comprising the recombinant antigen polypeptide described in any of any one of the preceding embodiments.
  • Embodiment 18 A cell comprising the polynucleotide of embodiment 17.
  • Embodiment 19 A vaccine composition comprising a plurality of the influenza antigen-adjuvant complexes of any of any one of the preceding embodiments.
  • Embodiment 20 A method for eliciting an immune response in a mammal comprising administering the vaccine composition of embodiment 19 to the mammal.
  • Embodiment 21 A method of preparing a recombinant vaccine composition comprising
  • Embodiment 22 A method of preparing a recombinant vaccine composition comprising
  • Embodiment 23 The method of embodiment 22, where the recombinant antigen polypeptide comprises one or more auxiliary elements.
  • Embodiment 24 The method of embodiment 23, wherein the one or more auxiliary elements are selected from the group consisting of a polyhistidine tag and a trimerization domain.
  • Embodiment 25 A recombinant vaccine composition produced by the method of embodiments 22-24.
  • plasmids were transformed into StellarTM cells, isolated by Maxiprep kits (NucleoBond Xtra Maxi kit, Macherey Nagel), filtered through a sterile 0.45-pm membrane in a biosafety cabinet and stored at -20 °C.
  • Expi-293F cells were cultured at 37 °C under constant shaking (120 rpm) in a humidified CO2 (8%) incubator. Expi-293F cells were transfected at a density of 3-4 x 10 6 cells/mL. For 200 mL transfection of antigen proteins, the transfection mixture was made by adding 120 pg plasmid DNA (from Maxiprep) to 20 mL expression media, followed by the dropwise addition of 260 pL FectoPro transfection reagent (Polyplus) with vigorous mixing. Transfection mixtures were incubated at room temperature for 10 minutes before being transferred to Expi-293F cells.
  • D-glucose (4 g/L, Sigma-Aldrich) and valproic acid (3 mM, Acros Organics) were added to the cells immediately post-transfection to increase recombinant protein production.
  • Cells were boosted again with D-glucose three days posttransfection and harvested on day four by centrifugation at 7000 x for five min. The supernatant was filtered through a 0.22-pm membrane for subsequent purification processes.
  • Antigen proteins with hexahistidine tags were purified with HisPurTM Ni-NTA resin (Thermo Fisher). Briefly, the filtered supernatant from Expi-293F cells was mixed with Ni- NTA resin (1 mL resin per liter supernatant) and incubated at 4 °C overnight. The mixture was then passed through a gravity-flow column, washed with 20 mM imidazole in HEPES buffer saline (HBS, 20 mM HEPES, pH 7.4, 150 mM NaCl), and then eluted with 250 mM imidazole in HBS.
  • HBS HEPES buffer saline
  • Size-exclusion chromatography— multi-angle light scattering (SEC-MALS) analysis was performed on a 1260 Infinity II high-performance liquid chromatography system (Agilent) coupled with a miniDAWN and Optilab detectors (Wyatt Technologies) for light scattering and refractive index analysis. Purified protein samples were loaded onto a SuperdexTM 200 column (Increase 3.2/300, Cytiva) sequentially for analysis. ASTRA software (Wyatt Technologies) was used for data analysis.
  • mAbs were serially diluted (10-fold dilution starting from 20 nM) and then added to the ELISA plates for one-hour incubation at room temperature. Rabbit anti-human IgG, HRP- conjugated (1 :4,000) was added for one-hour incubation before rinsing with PBST six times.
  • alum-based ELISA Nunc 96-well MaxiSorp plates were coated with ZsGreen- Avi-His-12D (4 pg/mL in DPBS, 60 pL per well) for one hour at room temperature. These plates were washed three times with Milli-Q H2O and then blocked with ChonBlock overnight at 4 °C. For subsequent steps, all dilutions were made in DPBS with 0.05% Tween- 20 and 0.1% BSA unless otherwise noted, and ELISA plates were rinsed with PBST in between steps. Alum (100 pg/mL in HBS) was added to the plates and incubated for one hour at room temperature.
  • HA or reoriented HA (2 pg/mL) was added to the plates and incubated for one hour at room temperature.
  • mAbs were serially diluted (10-fold dilution starting from 20 nM) and then added to the ELISA plates for one-hour incubation at room temperature.
  • Rabbit anti-human IgG, HRP-conjugated (1 :4,000) was added for one-hour incubation before rinsing with PBST six times.
  • ELISA plates were developed with the TMB substrate for five minutes and terminated with sulfuric acid. Absorbance at 450 nm was recorded on a microplate reader.
  • head-directed and stem-directed mAbs bound reoHZHA in streptavidin-based ELISAs, while there was a clear decrease in binding of head-directed mAb (FluA-20) when reoHZHA was adsorbed on alum, suggesting an “upside down” configuration where head epitopes were much less accessible.
  • H7-SH fragment 1 corresponding to amino acid residues 1-147 of H7-SH (SEQ ID NO: 1)
  • H7-SH fragment 2 corresponding to amino acid residues 148-497 of H7-SH (SEQ ID NO: 1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne de nouvelles compositions de vaccin comprenant un antigène H7 HA modifié lié à la surface d'un adjuvant ou d'un support par des interactions électrostatiques. L'antigène de la composition de vaccin est présenté dans une orientation définie sur une surface d'adjuvant de telle sorte que l'accessibilité de l'épitope est modifiée et qu'une réponse immunitaire est redirigée vers des épitopes spécifiques. Dans certains modes de réalisation, la composition de vaccin comprend un ou plusieurs polypeptides d'antigène recombinés adsorbés sur une particule d'alun. Dans certains modes de réalisation, le polypeptide antigénique recombiné comprend une région de groupes carboxyliques répétitifs (RRC) ou une région de groupes lysyl/guanidino répétitifs (RRL).
PCT/US2024/034466 2023-06-27 2024-06-18 Conception de candidats de vaccin universel contre la grippe par réorientation d'antigène Ceased WO2025006263A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363510395P 2023-06-27 2023-06-27
US63/510,395 2023-06-27

Publications (2)

Publication Number Publication Date
WO2025006263A2 true WO2025006263A2 (fr) 2025-01-02
WO2025006263A3 WO2025006263A3 (fr) 2025-03-20

Family

ID=93940127

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/034466 Ceased WO2025006263A2 (fr) 2023-06-27 2024-06-18 Conception de candidats de vaccin universel contre la grippe par réorientation d'antigène

Country Status (1)

Country Link
WO (1) WO2025006263A2 (fr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8080255B2 (en) * 2003-07-11 2011-12-20 Novavax Inc. Functional influenza virus like particles (VLPs)
PL4023249T3 (pl) * 2014-04-23 2025-03-10 Modernatx, Inc. Szczepionki z kwasem nukleinowym
US10363301B2 (en) * 2014-05-27 2019-07-30 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Stabilized influenza hemagglutinin stem region trimers and uses thereof
UY37620A (es) * 2017-02-28 2018-08-31 Univ Pennsylvania Vacunas contra la gripe mediadas por aav novedosas
EP4415753A1 (fr) * 2021-10-15 2024-08-21 CZ Biohub SF, LLC Ingénierie de liaison d'antigène à, et orientation sur, des adjuvants pour des réponses humorales améliorées et une immunofocalisation

Also Published As

Publication number Publication date
WO2025006263A3 (fr) 2025-03-20

Similar Documents

Publication Publication Date Title
KR20190056382A (ko) 안정화된 그룹 2 인플루엔자 헤마글루티닌 줄기 영역 삼량체 및 그의 용도
KR20210018205A (ko) 항원성 OspA 폴리펩타이드
JP7146926B2 (ja) Ｃｄ４ヘルパーｔ細胞エピトープの融合ペプチドおよびそのワクチン
AU2021392894B2 (en) Donor strand complemented fimh
EP4047013A1 (fr) Protéine porteuse ayant une mutation dirigée sur site et son utilisation dans la préparation d'un vaccin
US20240093159A1 (en) Virus-like particles and methods of production thereof
KR20150094697A (ko) 향상된 특성을 갖는 변형된 코일드 코일 유형 단백질
CA3197971A1 (fr) Vaccin a nanoparticules a base de proteine pour metapneumovirus
US20120100165A1 (en) Drug transporter, and adjuvant and vaccine each utilizing same
CN110548135B (zh) 磷酸化多肽抗原疫苗及其制备方法和应用
US20260055428A1 (en) Modified virus-like particles of cmv
WO2023064631A1 (fr) Ingénierie de liaison d'antigène à, et orientation sur, des adjuvants pour des réponses humorales améliorées et une immunofocalisation
CN119462963A (zh) 镜像偶联的蛋白质纳米颗粒缀合物及其应用
WO2025006263A2 (fr) Conception de candidats de vaccin universel contre la grippe par réorientation d'antigène
WO2025222028A1 (fr) Conception de candidats universels de vaccin contre le virus de la grippe h5 par réorientation d'antigène
JP6902804B2 (ja) Ｂ型肝炎ウイルス様粒子をアジュバントとして含むワクチン組成物
WO2016091181A1 (fr) Nouvelle structure protéique produite par un anticorps efficace et utilisée pour l'immunisation
CN114699521A (zh) 基于金属硫蛋白家族的免疫佐剂及其应用
CN115916237A (zh) 抗病毒病原体的疫苗
US20250281587A1 (en) Veterinary compositions of modified virus-like particles of cmv and feline il-1 beta mutein antigens
WO2025153824A1 (fr) Il31-vlp et leurs utilisations médicales
CN118557718A (zh) 一种以peg10蛋白为载体的纳米颗粒及其制备方法和应用
CN117777304A (zh) 呼吸道相关病毒纳米蛋白颗粒及其制备方法和用途
HK40072140A (en) Carrier protein with site-directed mutation and use thereof in preparation of vaccine

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE